Search Results
Your search for 27 matches 3369 pages
Showing 3051 - 3100SABCS 2015: Pathologic Complete Response to Presurgery Chemotherapy Improves Survival for Patients With Triple-Negative Breast Cancer
Patients with stage II or stage III triple-negative breast cancer who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery...
Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer
In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...
Prognostic Factors in Men With Brain Metastases From Germ Cell Tumors
As reported in the Journal of Clinical Oncology, Feldman et al, of the Global Germ Cell Cancer Group, identified prognostic factors in men with brain metastases from germ cell cancer at initial diagnosis or relapse. Overall survival was better in patients with metastases at diagnosis, a greater...
ASH 2015: Two Studies Focus on Treatment for Cancer-Associated Thrombosis
Two studies presented at the 57th American Society of Hematology (ASH) Annual Meeting examine the common problem of cancer-associated thrombosis. One looked to validate dosing guidelines for avoiding chemotherapy-induced thrombocytopenia, a common autoimmune response to therapy; the second compared ...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration today approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC....
Single-Institution Experience Indicates Improved Outcomes With Higher Radiotherapy Doses in Inoperable Intrahepatic Cholangiocarcinoma
In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Tao et al found that use of higher radiotherapy doses was associated with prolonged local control and overall survival in patients with inoperable intrahepatic cholangiocarcinoma. Overall survival was...
Investigational NAE Inhibitor Pevonedistat Shows Potential Activity in Patients With Relapsed/Refractory Lymphoma
A phase I study evaluating the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma has found...
Pooled Analysis Indicates That Low but Not High BMI Is Associated With Poorer Outcome in Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Renfro et al found that low but not high body mass index (BMI) was associated with poorer progression-free and overall survival in patients receiving first-line treatment for metastatic colorectal cancer. The analysis included individual...
Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia
In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...
29-Year Single-Center Longitudinal Experience Indicates 2% Annual Risk of Breast Cancer in Lobular Carcinoma in Situ
As reported by King et al in the Journal of Clinical Oncology, 29-year longitudinal experience at Memorial Sloan Kettering Cancer Center indicates an annual 2% risk of breast cancer in women with lobular carcinoma in situ. Risk was reduced with chemoprevention. Study Details The study involved...
Second-Line Lenvatinib Plus Everolimus Improves Progression-Free Survival vs Everolimus in Metastatic Renal Cell Carcinoma in Phase II Trial
In a phase II trial reported in The Lancet Oncology, Motzer et al found that the combination of the multi–tyrosine kinase inhibitor lenvatinib (Lenvima) plus the mTOR inhibitor everolimus (Afinitor) significantly improved progression-free survival vs everolimus alone in patients with...
ASTRO 2015: Androgen-Deprivation Therapy for 2 Years After Radiotherapy Improves Disease-Free Survival in Patients With Advanced Prostate Cancer
A long-term follow-up of RTOG 9202 indicated that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen-deprivation therapy after radiation therapy plus short-term androgen-deprivation therapy improved disease-free survival by 60%, compared to patients...
ASTRO 2015: Image-Guided Intensity-Modulated Radiation Therapy Reduces Bowel Side Effects in Cervical Cancer Patients
For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IMRT) resulted in a 14% reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3D CRT), according to...
ASTRO 2015: Frequent Post-Treatment Follow-up by Advance Practice Nurses Improves Care for Patients With High-Risk Head and Neck Cancer
For high-risk patients who receive chemoradiotherapy for head and neck cancer, frequent follow-up appointments conducted by advance practice nurses (APNs) in a clinical outpatient setting allowed for more intensive symptom management, resulting in fewer post-treatment emergency room visits and...
How Physicians Communicate With Parents May Discourage HPV Vaccination of Adolescents
A nationwide online survey of 776 pediatricians and family physicians assessing the quality of their human papillomavirus (HPV) vaccine recommendations to parents has found that a sizable minority of physicians—27%—said they do not strongly endorse HPV vaccination, and 26% and 39%...
Clergy Religious Beliefs Are Associated With Greater ICU Care in Congregants’ Final Days
A survey exploring the relationship between spiritual support and end-of-life care by evaluating clergy members’ opinions and experiences related to care provided to congregants at the end of their life has found that a majority of clergy endorse religious beliefs regarding their...
12-Year Ipsilateral Breast Invasive Recurrence in 7.5% to 13.4% of Women With Low-Risk DCIS Receiving Surgical Excision Without Radiation
As reported by Solin et al in Journal of Clinical Oncology, 12-year results from the ECOG-ACRIN E5194 trial indicate that among women with ductal carcinoma in situ (DCIS) with low-risk clinical and pathologic characteristics, surgical excision without radiation therapy was associated with...
Cardiovascular Prevention Trial Shows Reduction in Invasive Breast Cancer Risk With Mediterranean Diet Supplemented by Extra-Virgin Olive Oil
As reported in JAMA Internal Medicine by Toledo et al, a large Spanish primary prevention nutrition intervention trial in patients at high cardiovascular risk (PREDIMED) showed a large reduction in risk for invasive breast cancer among women 60 to 80 years of age who were randomly assigned to the...
Telomerase Inhibitor Imetelstat Shows Activity in Myelofibrosis
In a pilot study reported in The New England Journal of Medicine, Tefferi et al found that imetelstat, which targets the RNA template of telomerase reverse transcriptase, produced responses in patients with myelofibrosis. Treatment was associated with myelosuppression in some patients. Current...
ECC 2015: Pembrolizumab in Patients With Advanced Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Trial
Pembrolizumab (Keytruda), an anti–PD-1 therapy, may be effective as monotherapy in patients with advanced unresectable nasopharyngeal carcinoma whose tumors express programmed cell death-ligand 1 (PD-L1). Data from a phase Ib study, KEYNOTE-028, showed an overall response rate of 22.2% in 27...
ECC 2015: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: Results of the IMvigor 210 Study
At the 2015 European Cancer Congress in Vienna, Austria, early results were announced (Abstract 21LBA) from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (anti–PD-L1; MPDL3280A) in people with locally advanced or metastatic urothelial...
ECC 2015: Lung and Gastrointestinal Neuroendocrine Tumors and Results From the RADIANT-4 Trial
An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...
ECC 2015: Advanced Gastrointestinal Neuroendocrine Tumors and Results From the NETTER-1 Trial
Results from a multicenter randomized international trial of an innovative treatment show a marked improvement in the length of time patients with midgut neuroendocrine tumors experience progression-free survival, researchers reported at the 2015 European Cancer Congressin Vienna, Austria, on...
ECC 2015: Tackling the Global Shortfall in Radiotherapy
Millions of people are unable to receive necessary treatment worldwide because of a chronic underinvestment in radiotherapy resources, according to a major new Commission on access to radiotherapy, published in by Atun et al in The Lancet Oncology, and presented at the 2015 European Cancer Congress ...
ECC 2015: Children Exposed to Prenatal Cancer Treatment Show Normal Mental Processes and Heart Function
In a special session on cancer in pregnancy at the 2015 European Cancer Congress (Abstract 3205), Frédéric Amant, MD, PhD, said that new results from a study of 129 children, aged 1–3, born after prenatal exposure to cancer treatment, showed normal development of their...
ECC 2015: Nivolumab Improves Overall Survival in Patients With Advanced Kidney Cancer
The targeted drug nivolumab (Opdivo) significantly prolonged survival in patients with advanced kidney cancer whose disease had progressed after their first treatment, according to the results (Abstract 3LBA) presented at the 2015 European Cancer Congress (ECC) in Vienna, Austria, and published...
ECC 2015: Nivolumab Is More Effective Than Docetaxel in Extending Overall Survival in Advanced Nonsquamous NSCLC
A randomized phase III study by Borghaei et al evaluating the efficacy and safety of nivolumab (Opdivo) vs docetaxel in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy has found that nivolumab improved overall survival, 12.2...
Ruxolitinib-Capecitabine May Benefit Patients With Gemcitabine-Pretreated Metastatic Pancreatic Cancer With Systemic Inflammation
In a randomized phase II trial reported in the Journal of Clinical Oncology, Hurwitz et al found no significant survival benefit of adding the JAK1/JAK2 inhibitor ruxolitinib (Jakafi) to capecitabine in patients with advanced pancreatic adenocarcinoma who had treatment failure with gemcitabine....
Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Conventional Chemotherapy in Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in the Journal of Clinical Oncology, Demetri et al found that treatment with trabectedin significantly improved progression-free survival vs dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior conventional chemotherapy. Interim analysis of...
Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...
Long-Term Remissions Reported in CLL Personalized Cell Therapy Trial
In the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL), 8 of 14 patients responded to the therapy, with some complete remissions continuing past 4.5 years. These results, published by Porter et al in Science Translational...
BRAF V600 Mutation Appears to Be Targetable Oncogene in Some but Not All Nonmelanoma Cancers
In a phase II histology-independent basket study reported in The New England Journal of Medicine, Hyman et al found that the BRAF V600 kinase inhibitor vemurafenib (Zelboraf) exhibited activity in some but not all nonmelanoma cancers with BRAF V600 mutations. Study Details In the study, 122...
Long-Term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs May Be Associated With Reduced Colorectal Cancer Risk
A large population-based control study of the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs and colorectal cancer risk has found that taking 75 mg to 150 mg of aspirin for 5 years or longer was associated with a 27% reduced risk of colorectal cancer. In addition, 5 or more...
Organ Transplant Recipients May Be More Likely to Develop Aggressive Melanoma
Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant and three times more likely to die of the skin cancer, suggested new research by a multi-institutional team. The findings, reported by Robbins et al in the Journal of Investigative...
Study Finds Music Therapy Lowers Anxiety During Surgical Breast Biopsies
A first-of-its-kind study published by Bradley Palmer et al in the Journal of Clinical Oncology found that music therapy lessened anxiety for women undergoing surgical breast biopsies for cancer diagnosis and treatment. The 2-year study, conducted at University Hospitals (UH) Seidman Cancer Center, ...
Researchers Identify Nerve-Guiding Protein That May Be Associated With Pancreatic Cancer Metastasis
Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease metastasizes in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer and were published by Foley et...
Limited Resection Not Equivalent to Lobectomy for Survival in Older Patients With Early-Stage Lung Cancer
In an analysis reported in the Journal of Clinical Oncology, Veluswamy et al found that limited resection was not equivalent to lobectomy in overall survival among older patients with stage IA invasive adenocarcinoma or squamous cell carcinoma of the lung. Among patients with adenocarcinoma,...
Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer
In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...
Delay in Treatment, Missed Diagnostic Testing Found Among Patients With Lung Cancer
Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to findings published by Faris et al in The Annals of Thoracic Surgery. The 5-year relative ...
Involved-Field Radiotherapy May Be Best Option for Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
As reported by Eichenauer and colleagues in the Journal of Clinical Oncology, an analysis of long-term outcomes suggests that involved-field radiotherapy may be the best treatment option in patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma. Study Details The study involved...
ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Van Poznak et al, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer. The statement is based on an ASCO expert panel assessment of systematic reviews, ...
NCIC MA.20 Trial: Addition of Regional Nodal Irradiation in Early Breast Cancer Improves Disease-Free but Not Overall Survival
In a phase III trial (National Cancer Institute of Canada [NCIC] Clinical Trials Group MA.20) reported in The New England Journal of Medicine, Whelan et al found that the addition of regional nodal irradiation to whole-breast irradiation did not improve overall survival in women with node-positive...
Omitting Doxorubicin From Postoperative Chemotherapy Has No Significant Survival Effect in Intermediate-Risk Wilms Tumor
In a phase III noninferiority trial (SIOP WT 2001) reported in The Lancet, Pritchard-Jones et al in the SIOP (International Society of Paediatric Oncology) Renal Tumours Study Group found that omission of doxorubicin from postoperative chemotherapy for stage II to III histologic intermediate-risk...
FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...
Low Incidence of Infusion-Related Reactions Reported With 30-Minute Ipilimumab Infusion
In a single-institution study reported in the Journal of Clinical Oncology, Momtaz et al found that the rate of infusion-related reactions remained acceptably low when ipilimumab (Yervoy) 3 mg/kg was infused over 30 minutes in patients with advanced melanoma. The currently approved dose of...
No Benefit of Adding Gefitinib to Platinum-Based Doublet in EGFR-Mutant NSCLC After Progression on First-Line Gefitinib
In a phase III IMPRESS trial reported in The Lancet Oncology, Soria et al found no progression-free survival benefit of adding gefitinib (Iressa) to platinum-based doublet chemotherapy in patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC) who had acquired resistance to...
Afatinib Improves Progression-Free Survival vs Erlotinib in Second-Line Treatment of Advanced Squamous Cell Carcinoma of the Lung
In the phase III LUX-Lung 8 trial reported in The Lancet Oncology, Soria et al found that the irreversible ErbB-family inhibitor afatinib (Gilotrif) significantly improved progression-free and overall survival vs the EGFR tyrosine kinase inhibitor erlotinib as second-line treatment in patients with ...
Pembrolizumab Increases Progression-Free Survival vs Chemotherapy in Ipilimumab-Refractory Advanced Melanoma
In the randomized phase II KEYNOTE-002 trial reported in The Lancet Oncology, Ribas et al found that treatment with the anti–PD-1 antibody pembrolizumab (Keytruda) prolonged progression-free survival vs investigator-choice chemotherapy in patients with advanced melanoma progressing on...
Study Finds More Selective Ordering of Breast Biomarker Tests Could Save Millions in Health-Care Dollars
A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health-care spending without compromising care, according to Johns Hopkins researchers. Specifically,...
Community-Based Trial Suggests No Benefit of Adding Thalidomide or Melphalan to Bortezomib-Based First-Line Treatment of Myeloma
In the U.S. community-based phase IIIB UPFRONT trial reported in the Journal of Clinical Oncology, Niesvizky et al found no benefit of adding thalidomide (Thalomid) or melphalan to first-line bortezomib (Velcade)-based treatment in transplant-ineligible myeloma patients. Study Details In the...
